Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Status:
RECRUITING
Trial end date:
2031-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.